Statin treatment for patients with paroxysmal atrial fibrillation A J-RHYTHM substudy

Eiichi Watanabe, Takeshi Yamashita, Shinya Suzuki, Tetsunori Saikawa, Makoto Hirai, Tsutomu Yamazaki, Hiroshi Ohtsu, Satoshi Ogawa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Recent clinical evidence and animal experiments support the belief that statins have beneficial effects on cardiovascular outcomes and prevention of atrial fibrillation (AF). We investigated whether the use of statins reduces the mortality, morbidity, and recurrence rate of AF in patients with paroxysmal AF. A post hoc analysis of the Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study was conducted. Of the 823 patients with paroxysmal AF in the J-RHYTHM study, 101 (12.3%) were receiving a statin at baseline. Patients taking statins were older and more likely to have hypertension, dyslipidemia, coronary artery disease, and ischemic stroke compared to patients not taking statins. During a mean follow-up period of 19.3 months, 40 patients (5.5%) reached the primary endpoint (a composite of all-cause death, stroke, systemic embolism, major bleeding, and hospitalization for heart failure) and 140 patients (19.4%) experienced a recurrence of AF. Multivariate Cox proportional- hazard regression analysis revealed statin use was not associated with improved mortality and morbidity (hazard ratio [HR] 0.409, 95% confidence interval [CI] 0.113-1.482), or a decreased risk of AF recurrence (HR 0.662, 95% CI 0.299-1.466). This analysis provides evidence that statin use did not affect clinical outcomes in patients with paroxysmal AF and emphasizes the need for randomized clinical trials defining more clearly the role of statins in treating AF.

Original languageEnglish
Pages (from-to)103-106
Number of pages4
JournalInternational Heart Journal
Volume52
Issue number2
DOIs
Publication statusPublished - 25-04-2011

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atrial Fibrillation
Therapeutics
Recurrence
Stroke
Confidence Intervals
Morbidity
Mortality
Dyslipidemias
Embolism
Coronary Artery Disease
Cause of Death
Hospitalization
Randomized Controlled Trials
Heart Failure
Regression Analysis
Hemorrhage
Hypertension

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Watanabe, E., Yamashita, T., Suzuki, S., Saikawa, T., Hirai, M., Yamazaki, T., ... Ogawa, S. (2011). Statin treatment for patients with paroxysmal atrial fibrillation A J-RHYTHM substudy. International Heart Journal, 52(2), 103-106. https://doi.org/10.1536/ihj.52.103
Watanabe, Eiichi ; Yamashita, Takeshi ; Suzuki, Shinya ; Saikawa, Tetsunori ; Hirai, Makoto ; Yamazaki, Tsutomu ; Ohtsu, Hiroshi ; Ogawa, Satoshi. / Statin treatment for patients with paroxysmal atrial fibrillation A J-RHYTHM substudy. In: International Heart Journal. 2011 ; Vol. 52, No. 2. pp. 103-106.
@article{55a2a0e7ab06491589cb63dd40166779,
title = "Statin treatment for patients with paroxysmal atrial fibrillation A J-RHYTHM substudy",
abstract = "Recent clinical evidence and animal experiments support the belief that statins have beneficial effects on cardiovascular outcomes and prevention of atrial fibrillation (AF). We investigated whether the use of statins reduces the mortality, morbidity, and recurrence rate of AF in patients with paroxysmal AF. A post hoc analysis of the Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study was conducted. Of the 823 patients with paroxysmal AF in the J-RHYTHM study, 101 (12.3{\%}) were receiving a statin at baseline. Patients taking statins were older and more likely to have hypertension, dyslipidemia, coronary artery disease, and ischemic stroke compared to patients not taking statins. During a mean follow-up period of 19.3 months, 40 patients (5.5{\%}) reached the primary endpoint (a composite of all-cause death, stroke, systemic embolism, major bleeding, and hospitalization for heart failure) and 140 patients (19.4{\%}) experienced a recurrence of AF. Multivariate Cox proportional- hazard regression analysis revealed statin use was not associated with improved mortality and morbidity (hazard ratio [HR] 0.409, 95{\%} confidence interval [CI] 0.113-1.482), or a decreased risk of AF recurrence (HR 0.662, 95{\%} CI 0.299-1.466). This analysis provides evidence that statin use did not affect clinical outcomes in patients with paroxysmal AF and emphasizes the need for randomized clinical trials defining more clearly the role of statins in treating AF.",
author = "Eiichi Watanabe and Takeshi Yamashita and Shinya Suzuki and Tetsunori Saikawa and Makoto Hirai and Tsutomu Yamazaki and Hiroshi Ohtsu and Satoshi Ogawa",
year = "2011",
month = "4",
day = "25",
doi = "10.1536/ihj.52.103",
language = "English",
volume = "52",
pages = "103--106",
journal = "International Heart Journal",
issn = "1349-2365",
publisher = "International Heart Journal Association",
number = "2",

}

Watanabe, E, Yamashita, T, Suzuki, S, Saikawa, T, Hirai, M, Yamazaki, T, Ohtsu, H & Ogawa, S 2011, 'Statin treatment for patients with paroxysmal atrial fibrillation A J-RHYTHM substudy', International Heart Journal, vol. 52, no. 2, pp. 103-106. https://doi.org/10.1536/ihj.52.103

Statin treatment for patients with paroxysmal atrial fibrillation A J-RHYTHM substudy. / Watanabe, Eiichi; Yamashita, Takeshi; Suzuki, Shinya; Saikawa, Tetsunori; Hirai, Makoto; Yamazaki, Tsutomu; Ohtsu, Hiroshi; Ogawa, Satoshi.

In: International Heart Journal, Vol. 52, No. 2, 25.04.2011, p. 103-106.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Statin treatment for patients with paroxysmal atrial fibrillation A J-RHYTHM substudy

AU - Watanabe, Eiichi

AU - Yamashita, Takeshi

AU - Suzuki, Shinya

AU - Saikawa, Tetsunori

AU - Hirai, Makoto

AU - Yamazaki, Tsutomu

AU - Ohtsu, Hiroshi

AU - Ogawa, Satoshi

PY - 2011/4/25

Y1 - 2011/4/25

N2 - Recent clinical evidence and animal experiments support the belief that statins have beneficial effects on cardiovascular outcomes and prevention of atrial fibrillation (AF). We investigated whether the use of statins reduces the mortality, morbidity, and recurrence rate of AF in patients with paroxysmal AF. A post hoc analysis of the Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study was conducted. Of the 823 patients with paroxysmal AF in the J-RHYTHM study, 101 (12.3%) were receiving a statin at baseline. Patients taking statins were older and more likely to have hypertension, dyslipidemia, coronary artery disease, and ischemic stroke compared to patients not taking statins. During a mean follow-up period of 19.3 months, 40 patients (5.5%) reached the primary endpoint (a composite of all-cause death, stroke, systemic embolism, major bleeding, and hospitalization for heart failure) and 140 patients (19.4%) experienced a recurrence of AF. Multivariate Cox proportional- hazard regression analysis revealed statin use was not associated with improved mortality and morbidity (hazard ratio [HR] 0.409, 95% confidence interval [CI] 0.113-1.482), or a decreased risk of AF recurrence (HR 0.662, 95% CI 0.299-1.466). This analysis provides evidence that statin use did not affect clinical outcomes in patients with paroxysmal AF and emphasizes the need for randomized clinical trials defining more clearly the role of statins in treating AF.

AB - Recent clinical evidence and animal experiments support the belief that statins have beneficial effects on cardiovascular outcomes and prevention of atrial fibrillation (AF). We investigated whether the use of statins reduces the mortality, morbidity, and recurrence rate of AF in patients with paroxysmal AF. A post hoc analysis of the Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM) study was conducted. Of the 823 patients with paroxysmal AF in the J-RHYTHM study, 101 (12.3%) were receiving a statin at baseline. Patients taking statins were older and more likely to have hypertension, dyslipidemia, coronary artery disease, and ischemic stroke compared to patients not taking statins. During a mean follow-up period of 19.3 months, 40 patients (5.5%) reached the primary endpoint (a composite of all-cause death, stroke, systemic embolism, major bleeding, and hospitalization for heart failure) and 140 patients (19.4%) experienced a recurrence of AF. Multivariate Cox proportional- hazard regression analysis revealed statin use was not associated with improved mortality and morbidity (hazard ratio [HR] 0.409, 95% confidence interval [CI] 0.113-1.482), or a decreased risk of AF recurrence (HR 0.662, 95% CI 0.299-1.466). This analysis provides evidence that statin use did not affect clinical outcomes in patients with paroxysmal AF and emphasizes the need for randomized clinical trials defining more clearly the role of statins in treating AF.

UR - http://www.scopus.com/inward/record.url?scp=79954496028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954496028&partnerID=8YFLogxK

U2 - 10.1536/ihj.52.103

DO - 10.1536/ihj.52.103

M3 - Article

C2 - 21483169

AN - SCOPUS:79954496028

VL - 52

SP - 103

EP - 106

JO - International Heart Journal

JF - International Heart Journal

SN - 1349-2365

IS - 2

ER -